Sign In
Buy CDXS
$1.40
-0.0800 (-5.41%)
At Close: Jul 31, 2026
Codexis to Report First Quarter 2024 Financial Results on May 2
04:05pm, Thursday, 18'th Apr 2024
REDWOOD CITY, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first qua
Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board
07:05am, Thursday, 11'th Apr 2024
Cobb adds RNA industry operations and commercial expertise to support continued development of ECO Synthesis™ manufacturing platform Cobb adds RNA industry operations and commercial expertise to su
Codexis, Inc. (CDXS) Q4 2023 Earnings Call Transcript
10:39pm, Wednesday, 28'th Feb 2024
Codexis, Inc. (CDXS) Q4 2023 Earnings Call Transcript
Codexis (CDXS) Tops Q4 Earnings and Revenue Estimates
07:51pm, Wednesday, 28'th Feb 2024
Codexis (CDXS) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.16 per share. This compares to loss of $0.19 per share a year ago.
Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results
04:05pm, Wednesday, 28'th Feb 2024
Anticipate 2024 Product Revenue Growth of at Least 10% vs. 2023 Excluding Enzyme Sales Related to PAXLOVID™ Recently Announced Debt Financing Reinforces Strong Financial Position with Projected Runw
Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche
04:05pm, Monday, 26'th Feb 2024
REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an agreement with Roche for an exclusive
Codexis to Participate in TD Cowen 44th Annual Health Care Conference
08:05am, Monday, 26'th Feb 2024
REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the TD Cowen 44th Annual Health Care
Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board
08:05am, Tuesday, 20'th Feb 2024
Board expertise encompasses oligonucleotide research, development, manufacturing and commercialization to support development of ECO Synthesis™ manufacturing platform Board expertise encompasses oli
WIX Set to Report Q4 Earnings: Here's What You Should Know
08:56am, Friday, 16'th Feb 2024
WIX Q4 performance is likely to have benefited from an uptake of new products and improvement in the user base.
Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28
04:05pm, Wednesday, 14'th Feb 2024
REDWOOD CITY, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the fourth qua
Term loan agreement enables Company to accelerate development and enhance commercialization of ECO Synthesis™ manufacturing platform for RNAi therapeutics
seqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT General Meeting
04:05pm, Thursday, 01'st Feb 2024
TnX transposase development collaboration leverages strengths of both companies TnX transposase development collaboration leverages strengths of both companies
Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108
08:30am, Wednesday, 27'th Dec 2023
Company to retain economic interest in biotherapeutic asset while removing cash burn from development and commercialization costs Company to retain economic interest in biotherapeutic asset while remo
Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex® HiCap RNA Polymerase
04:06pm, Wednesday, 13'th Dec 2023
Deal creates strategic collaboration to enable more efficient RNA therapeutic development, providing a path to GMP-grade Codexis enzymes Deal creates strategic collaboration to enable more efficient
Codexis Announces Achievement of Gram-scale Synthesis with its ECO Synthesis™ Platform
04:05pm, Wednesday, 13'th Dec 2023
Milestone enables Codexis engineers to model the manufacturing process for RNAi therapeutics Company remains on track to initiate pre-commercial customer testing in 2024 REDWOOD CITY, Calif., Dec. 13,
